Knowledge of hepatitis C and awareness of reinfection risk among people who successfully completed direct acting antiviral therapy.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
23
11
2021
accepted:
08
03
2022
entrez:
23
3
2022
pubmed:
24
3
2022
medline:
6
5
2022
Statut:
epublish
Résumé
Hepatitis C virus (HCV) education may be changing following the simplification of HCV treatment and emergence of direct acting antiviral (DAA). We aimed to characterize HCV knowledge among people who recently completed DAA therapy. The Per-SVR (Preservation of Sustained Virologic Response) is a prospective cohort of patients who achieved a sustained virologic response upon successful completion of DAA therapy. The per-SVR study provided the sampling frame of participants who completed a psychometrically validated 19-item HCV knowledge scale at cohort entry (n = 227). To score the questionnaire, for each correct response one point was awarded, with no point for incorrect response. We assessed mean HCV knowledge score in the overall sample and mutually exclusive populations: people who inject drug (PWID) (n = 71); people with co-occurring HIV (n = 23); PWID and co-occurring HIV (n = 29), and others (n = 104) Using a latent class analysis based on distal outcome, we identified unobserved subgroups and assessed HCV knowledge amongst them. Total mean (SD) percent of correct responses were 83 (11) in the overall sample; 83 (10) in PWID; 79 (12) in people with co-occurring HIV; 81 (10) in PWID and co-occurring HIV, and 84 (11) in rest of the sample Three latent groups were identified: baby boomers who ever experienced homelessness (n = 126); women sex workers who ever experienced homelessness (n = 68); men who inject drug, ever experienced homelessness and had ever diagnosis of mental health disorders (n = 18). Mean percent of correct responses were 85 (8), 82 (11), 85 (10), in latent class 1, 2, and 3, respectively. Patients successfully treated with DAAs had a high HCV knowledge. High knowledge and awareness of reinfection among complex patient groups often facing barriers to HCV care is encouraging and emphasizes the positive outcomes of universal access to treatment.
Sections du résumé
BACKGROUND
Hepatitis C virus (HCV) education may be changing following the simplification of HCV treatment and emergence of direct acting antiviral (DAA). We aimed to characterize HCV knowledge among people who recently completed DAA therapy.
METHODS
The Per-SVR (Preservation of Sustained Virologic Response) is a prospective cohort of patients who achieved a sustained virologic response upon successful completion of DAA therapy. The per-SVR study provided the sampling frame of participants who completed a psychometrically validated 19-item HCV knowledge scale at cohort entry (n = 227). To score the questionnaire, for each correct response one point was awarded, with no point for incorrect response. We assessed mean HCV knowledge score in the overall sample and mutually exclusive populations: people who inject drug (PWID) (n = 71); people with co-occurring HIV (n = 23); PWID and co-occurring HIV (n = 29), and others (n = 104) Using a latent class analysis based on distal outcome, we identified unobserved subgroups and assessed HCV knowledge amongst them.
RESULTS
Total mean (SD) percent of correct responses were 83 (11) in the overall sample; 83 (10) in PWID; 79 (12) in people with co-occurring HIV; 81 (10) in PWID and co-occurring HIV, and 84 (11) in rest of the sample Three latent groups were identified: baby boomers who ever experienced homelessness (n = 126); women sex workers who ever experienced homelessness (n = 68); men who inject drug, ever experienced homelessness and had ever diagnosis of mental health disorders (n = 18). Mean percent of correct responses were 85 (8), 82 (11), 85 (10), in latent class 1, 2, and 3, respectively.
CONCLUSION
Patients successfully treated with DAAs had a high HCV knowledge. High knowledge and awareness of reinfection among complex patient groups often facing barriers to HCV care is encouraging and emphasizes the positive outcomes of universal access to treatment.
Identifiants
pubmed: 35320316
doi: 10.1371/journal.pone.0265811
pii: PONE-D-21-37237
pmc: PMC8942206
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0265811Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176
pubmed: 28404132
Int J Drug Policy. 2017 Sep;47:137-143
pubmed: 28347636
Gastroenterology. 2015 Mar;148(3):517-532.e3
pubmed: 25500423
Int J Infect Dis. 2020 Nov;100:27-33
pubmed: 32810594
CMAJ. 2017 Jun 26;189(25):E870-E871
pubmed: 28652485
MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):399-404
pubmed: 32271725
J Viral Hepat. 2013 Oct;20(10):708-14
pubmed: 24010645
Addict Behav. 1982;7(4):363-71
pubmed: 7183189
Hepatology. 2013 Apr;57(4):1333-42
pubmed: 23172780
Cochrane Database Syst Rev. 2001;(4):CD003183
pubmed: 11687177
J Viral Hepat. 2021 Oct;28(10):1340-1354
pubmed: 34310812
Subst Use Misuse. 2021;56(5):728-737
pubmed: 33682610
BMC Complement Med Ther. 2020 Jun 3;20(1):169
pubmed: 32493310
Stat Methodol. 2016 Sep;32:107-121
pubmed: 27695391
Struct Equ Modeling. 2013 Jan;20(1):1-26
pubmed: 25419096
Hepatology. 2010 Nov;52(5):1564-72
pubmed: 21038409
Drug Alcohol Depend. 2019 Jan 1;194:453-459
pubmed: 30503906
Clin Psychol Rev. 2017 Nov;57:208-225
pubmed: 28919323
Liver Int. 2019 Dec;39(12):2261-2272
pubmed: 31444846
Can Commun Dis Rep. 2014 Dec 18;40(19):429-436
pubmed: 29769874
Harm Reduct J. 2020 Sep 18;17(1):64
pubmed: 32948189
Hepatology. 2012 Apr;55(4):1058-69
pubmed: 22031335
Int J Environ Res Public Health. 2019 Jun 02;16(11):
pubmed: 31159479
J Subst Abuse Treat. 2007 Mar;32(2):189-98
pubmed: 17306727
Open Forum Infect Dis. 2018 Jul 31;5(7):ofy173
pubmed: 30090840
AIDS Care. 2018 Sep;30(9):1161-1167
pubmed: 29701075
Psychol Health Med. 2017 Jun;22(5):625-632
pubmed: 27268000
Scand J Caring Sci. 2009 Dec;23(4):801-8
pubmed: 19500309
MMWR Recomm Rep. 2012 Aug 17;61(RR-4):1-32
pubmed: 22895429
EBioMedicine. 2016 Oct;12:189-195
pubmed: 27596150
MMWR Morb Mortal Wkly Rep. 2015 May 8;64(17):453-8
pubmed: 25950251